

Sinfonia Biotherapeutics AB Awarded EU Horizon 2020 Phase 1 Research Grant

Huddinge, Sweden, Nov. 29, 2018 - - Sinfonia Biotherapeutics, an early-stage biotherapeutics company pioneering the development of bioreactor-delivered treatments for inherited and genetically-defined neurodegenerative diseases, announced today the award of a Horizon 2020 SME (Small and Medium-sized Enterprises) Instrument Phase 1 research grant from the European Union. The SME Phase 1 grant supports the preclinical development of iProg Therapy, the company's product candidate for the treatment of progranulin-related Frontotemporal Degeneration (GRN-FTD), a genetically-defined sub-population of patients with FTD.

"There is a critical unmet medical need for disease-modifying treatments for Frontotemporal Degeneration and related dementias. We are excited to be awarded a Horizon 2020 SME grant to help advance Sinfonia's development program for progranulin restorative therapy to treat progranulin-related FTD. This grant offers further validation of our innovative approach to treating inherited dementias" said Bob Blomquist, CEO, Sinfonia US.

About the European Union Horizon 2020 SME Instrument Grant Program

The European Union Horizon 2020 program funds high-potential innovation developed by SMEs through the SME instrument grant. The SME instrument is part of the European Innovation Council pilot, which offers Europe's brightest and boldest entrepreneurs the chance to request funding for breakthrough ideas with the potential to create entirely new markets or revolutionize existing ones. The SME Instrument grant program offers phased, progressive and complementary support to the development of out-of-the-box ideas. The Phase 1 grant is for exploring and assessing the technical feasibility and commercial potential of a breakthrough innovation that a company wants to develop and commercialize. Small and Medium-sized Enterprises with an EU base are eligible.

About Sinfonia Biotherapeutics

Sinfonia Biotherapeutics is an early-stage biotherapeutics company focused on developing bioreactor-delivered treatments for inherited and genetically-defined neurodegenerative diseases. Just as cancer is composed of many different subtypes, we think dementia is as well. Thus, to succeed where others have failed in developing dementia treatments, we are developing life-changing biologic therapies that target familial dementia subtypes with underlying disease mechanisms that are genetically-defined. We are utilizing bioreactor-based cell therapy to deliver biologics directly to affected brain tissues. iProg Therapy, our breakthrough, first-in-class progranulin restorative therapy in preclinical development with lead indication treatment for progranulin-related frontotemporal dementia (GRN-FTD), has demonstrated promising preclinical proof of concept results. The company's research and development laboratories are located in Huddinge, Sweden, while the business and finance office is located in Boulder, Colorado, USA.

Sinfonia Biotherapeutics Contact:

Bob Blomquist
CEO, Sinfonia US
+1 (303) 786-8310
bob@blomquist-associates.com